MX2023013688A - Métodos de tratamiento de trastornos relacionados con la mitocondria. - Google Patents

Métodos de tratamiento de trastornos relacionados con la mitocondria.

Info

Publication number
MX2023013688A
MX2023013688A MX2023013688A MX2023013688A MX2023013688A MX 2023013688 A MX2023013688 A MX 2023013688A MX 2023013688 A MX2023013688 A MX 2023013688A MX 2023013688 A MX2023013688 A MX 2023013688A MX 2023013688 A MX2023013688 A MX 2023013688A
Authority
MX
Mexico
Prior art keywords
methyl
methods
related disorders
treating mitochondria
dinitrophenoxy
Prior art date
Application number
MX2023013688A
Other languages
English (en)
Spanish (es)
Inventor
Diane Jorkasky
Shaharyar Khan
Original Assignee
Rivus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rivus Pharmaceuticals Inc filed Critical Rivus Pharmaceuticals Inc
Publication of MX2023013688A publication Critical patent/MX2023013688A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023013688A 2021-05-20 2022-05-19 Métodos de tratamiento de trastornos relacionados con la mitocondria. MX2023013688A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163191321P 2021-05-20 2021-05-20
US202163222841P 2021-07-16 2021-07-16
US202263307515P 2022-02-07 2022-02-07
PCT/US2022/029992 WO2022246039A1 (en) 2021-05-20 2022-05-19 Methods of treating mitochondria-related disorders

Publications (1)

Publication Number Publication Date
MX2023013688A true MX2023013688A (es) 2024-02-27

Family

ID=82020295

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013688A MX2023013688A (es) 2021-05-20 2022-05-19 Métodos de tratamiento de trastornos relacionados con la mitocondria.

Country Status (14)

Country Link
US (1) US20250177353A1 (https=)
EP (1) EP4340829A1 (https=)
JP (1) JP2024521709A (https=)
KR (1) KR20240021827A (https=)
AU (1) AU2022275935A1 (https=)
BR (1) BR112023024146A2 (https=)
CA (1) CA3219548A1 (https=)
CL (1) CL2023003441A1 (https=)
GE (1) GEAP202416398A (https=)
IL (1) IL308669A (https=)
JO (1) JOP20230298A1 (https=)
MX (1) MX2023013688A (https=)
TW (1) TW202313010A (https=)
WO (1) WO2022246039A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150759A1 (en) * 2022-02-07 2023-08-10 Rivus Pharmaceuticals, Inc. Methods of weight loss in a subject with elevated hba1c
TW202515545A (zh) * 2023-08-10 2025-04-16 大陸商深圳君聖泰生物技術有限公司 2,4-二硝苯酚之衍生物以及前藥、以及其組成物以及方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098641B1 (en) 1998-07-27 2016-04-27 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo

Also Published As

Publication number Publication date
EP4340829A1 (en) 2024-03-27
KR20240021827A (ko) 2024-02-19
JP2024521709A (ja) 2024-06-04
CL2023003441A1 (es) 2024-05-10
JOP20230298A1 (ar) 2023-11-19
US20250177353A1 (en) 2025-06-05
TW202313010A (zh) 2023-04-01
WO2022246039A1 (en) 2022-11-24
AU2022275935A1 (en) 2023-12-07
BR112023024146A2 (pt) 2024-01-30
CA3219548A1 (en) 2022-11-24
GEAP202416398A (en) 2024-01-25
IL308669A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
MX2023013688A (es) Métodos de tratamiento de trastornos relacionados con la mitocondria.
WO2002000218A3 (en) Methods of treating neutrophil-related diseases with topical anesthetics
Deek BPC 157 as potential treatment for COVID-19
CN103169822B (zh) 滑膜炎回药膏及其制备方法
NO20092581L (no) Kombinasjonsterapi av lavere urinveislidelser med alfa2delta-ligander og NSAID'er
IL318374A (en) Methods of administering nalbuphine
US20140212405A1 (en) Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions
JPH02180828A (ja) 男性不能症の治療用物質
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
CN102488768B (zh) 治疗痛风的中药药物
JP1793223S (ja) 治療用組織修復機
CN1261136C (zh) 治疗腰腿痛的外用贴膏
MX2024005374A (es) Metodos para tratar la enfermedad de celulas falciformes con voxelotor.
CN116173160A (zh) 一种外用消肿止痛组方及其应用
JPWO2022235557A5 (https=)
CN112823802A (zh) 一种治疗风湿性关节炎的外用中药液
Seifi et al. Effect of intravenous regional anesthesia with spinal block on foot surgeries: A double-blinded randomized clinical trial
CN114948853B (zh) 一种治疗周围性面瘫的中药外薰方及其制备方法和应用
TW202611065A (zh) pUDK-HGF注射液的用途
MXPA03000088A (es) Herramienta de impacto con extremo de accionamiento desprendible.
CN105232814A (zh) 一种治疗颅内血肿清除术后遗症的中药组合物
Juanping Acupuncture combined with cupping therapy for 30 cases of intractable hiccup
Zhong-li et al. Treatment of bile reflux gastritis by point-injection in 72 cases
Safarpour et al. 33 with Botulinum Neurotoxins
RU2295349C2 (ru) Способ лечения остеоартроза коленных суставов с использованием внутрисуставного введения препарата "хондролон"